🇺🇸 FDA

P1 · Therapeutic area intelligence

Oncology patent intelligence

Anticancer agents, immuno-oncology, ADC, and oncology patent filings — grants, expirations, and assignee activity.

Patents
1,930

Quick answer

1,930 US pharmaceutical patents in our index match Oncology title keywords (A61K/A61P). Cross-link to related drug therapeutic-area hubs and company patent portfolios for full IP context.

  1. US 9840470

    Targeting GLI proteins in human cancer by small molecules

    The Regents of the University of California · Granted Tue Dec 12 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 07 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 9833508

    Cancer therapeutics

    IMMIX BIOPHARMA, INC. · Granted Tue Dec 05 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 30 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 9828435

    Use of antibodies or antigen-binding fragments thereof that specifically bind semaphorin-4D to increase tumor infiltrating leukocyte frequency

    VACCINEX, INC. · Granted Tue Nov 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 9828432

    Cancer treatment and monitoring methods using OX40 agonists

    Providence Health & Services—Oregon · Granted Tue Nov 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 9820653

    Methods, systems, and devices for imaging microscopic tumors

    The Regents of the University of California · Granted Tue Nov 21 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9814789

    Radiopharmaceutical products for diagnosis and therapy of adrenal carcinoma

    Julius-Maximilians-Universitat Wurzburg · Granted Tue Nov 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9808524

    Combination of local and systemic immunomodulative therapies for melanoma and liver cancer

    Provectus Pharmatech, Inc. · Granted Tue Nov 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9808486

    Administration of kynurenine depleting enzymes for tumor therapy

    The Board of Regents of the University of Texas System · Granted Tue Nov 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 9808448

    Pharmaceutical compounds and use of same in cancer and tauopathies

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Nov 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9808543

    Iron garnet nanoparticles for cancer radiotherapy and chemotherapy

    The Board of Regents of the University of Texas System · Granted Tue Nov 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9801922

    Compositions and methods of treating cancer

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Oct 31 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9801873

    Methods for treating humans having brain cancer

    Nektar Therapeutics · Granted Tue Oct 31 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 9801954

    Lipid substitution on aminoglycoside based polymers: plasmid delivery, anticancer drug delivery and transgene expression

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Oct 31 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9804163

    Biomarkers for prostate cancer and methods for their detection

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 31 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9803021

    CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities

    The Regents of the University of California · Granted Tue Oct 31 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9789096

    Methods and compositions for selective and targeted cancer therapy

    The Board of Regents of the University of Texas System · Granted Tue Oct 17 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9790274

    Monoclonal antibodies targeting EpCAM for detection of prostate cancer lymph node metastases

    The Board of Regents of the University of Texas System · Granted Tue Oct 17 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9783855

    Cancer screening by detection of ultrastructural and molecular markers

    Northwestern University · Granted Tue Oct 10 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9770414

    Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent

    Pacira Pharmaceuticals, Inc. · Granted Tue Sep 26 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 21 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9771585

    miR-155 inhibitors for treating cutaneous T cell lymphoma (CTCL)

    MIRAGEN THERAPEUTICS, INC. · Granted Tue Sep 26 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 21 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 9765147

    Anti-CSFR1 antibody and anti PD-1 antibody combination therapy for cancer

    Five Prime Therapeutics, Inc. · Granted Tue Sep 19 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 9765337

    Phosphoribosyl pyrophosphate synthetase 2 (PRPS2) as a therapeutic target in cancer treatment

    The Regents of the University of California · Granted Tue Sep 19 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 9765142

    TEM8 antibodies and their use in treatment and detection of tumors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Sep 19 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 9763982

    Depletion of cancer stem cells

    The Regents of the University of California · Granted Tue Sep 19 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 9758556

    Compositions and methods for inhibiting tumor cells by inhibiting the transcription factor ATF5

    The Regents of the University of California · Granted Tue Sep 12 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 07 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 9758591

    Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis

    The Regents of the University of California · Granted Tue Sep 12 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 07 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 9758555

    Compositions and methods for inhibiting tumor cells by inhibiting the transcription factor ATF5

    The Regents of the University of California · Granted Tue Sep 12 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 07 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 9731023

    Somatostatin receptor-based cancer therapy

    The Board of Regents of the University of Texas System · Granted Tue Aug 15 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 10 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 9730954

    miRNAs as novel therapeutic adjuvants and biomarkers for the prognosis and treatment of drug resistant breast cancers

    The Board of Regents of the University of Texas System · Granted Tue Aug 15 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 10 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 9731011

    Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma

    EnGeneIC Molecular Delivery Pty Ltd · Granted Tue Aug 15 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 10 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 9732114

    Compounds having anti-adhesive effects on cancer cells

    The Board of Regents of the University of Texas System · Granted Tue Aug 15 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 10 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 9725475

    Arsenoplatin anti-cancer agents

    Northwestern University · Granted Tue Aug 08 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 03 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 9724350

    N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as IDH2 mutants inhibitors for the treatment of cancer

    Agios Pharmaceuticals, Inc. · Granted Tue Aug 08 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 03 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 9718835

    20(S)-sulfonylamidine derivatives of camptothecin and the use thereof as a potent antitumor agent

    China Medical University Hospital · Granted Tue Aug 01 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 27 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 9718866

    Colon and pancreas cancer peptidomimetics

    PRECISION BIOLOGICS, INC. · Granted Tue Aug 01 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 27 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 9713612

    Compounds for treatment of cancer

    Curegenix, Inc. · Granted Tue Jul 25 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 20 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 9707221

    Methods of treating cancer patients with farnesyltransferase inhibitors

    Kura Oncology, Inc. · Granted Tue Jul 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 9700639

    Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells

    Aura Biosciences, Inc. · Granted Tue Jul 11 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 9701733

    Maspin-based treatment of cancer

    Northwestern University · Granted Tue Jul 11 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 9688764

    Methods of treating breast cancer by administering anti-human prolactin receptor (PRLR) antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 27 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 22 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 9683025

    Methods and compositions for treating cancer and inflammatory diseases

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Jun 20 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 15 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 9676788

    Aza-epoxy-guaiane derivatives and treatment of cancer

    The United States of America, as represented by the Secretary, Health and Human Services · Granted Tue Jun 13 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 9675633

    miRNA for treating cancer and for use with adoptive immunotherapies

    The Board of Regents of the University of Texas System · Granted Tue Jun 13 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 9670549

    Gene expression signatures of neoplasm responsiveness to therapy

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jun 06 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 9670141

    (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, and related compounds as GABA aminotransferase inactivators for the treatment of epilepsy, addiction and hepatocellular carcinoma

    Northwestern University · Granted Tue Jun 06 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 9669004

    Daidzein analogs as treatment for cancer

    United States Department of Agriculture · Granted Tue Jun 06 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 9662327

    Phenyl and pyridinyl substituted piperidines and piperazines as inhibitors of IDH1 mutants and their use in treating cancer

    Agios Pharmaceuticals, Inc. · Granted Tue May 30 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 25 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 9663521

    Compounds and methods for the prevention and treatment of tumor metastasis and tumorigenesis

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue May 30 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 25 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many Oncology patents are indexed?

1,930 patents match our Oncology classifier (title keywords in USPTO records).

Is this legal or medical advice?

No — patent intelligence is for professional reference. Verify expiration and FTO with qualified patent counsel and primary USPTO records.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.